Analysis of therapeutic strategies of RUNX1-RUNX1T1-induced acute myeloid leukemia based on medical interventions on different stages of leukemogenesis

Langyi Zuo
DOI: https://doi.org/10.1117/12.2691830
2023-09-07
Abstract:RUNX1-RUNX1T1-fusion-induced acute myeloid leukemia accounts for nearly 5% of total AML instances, and the percentage becomes higher in M2 subtype AML (10-20%). Due to t(8;21) chromosomal translocation, the fused gene suppresses the expression of all RUNX1-mediated hematopoietic genes, inhibiting the normal differentiation of myeloid cells and inducing leukemogenesis. This type of AML involves menacing symptoms from the disease and persisting adverse effects from the therapy they received. Current research regarding this type of AML mainly focuses on random individual pharmaceutical targets and biomolecular pathways. However, more attention needs to be placed on prioritizing aspects regarding different aspects of this type of AML, and future research should devote more effort to it. This paper explores if there is a correlation between the complexity of the study and specific pharmaceutical targets or pathways it focuses on. By analyzing several recent studies related to RUNX1-RUNX1T1-induced AML, a conclusion is derived that the later stage of leukemogenesis of the research target or pathway belongs to, the more complicated process and resources will be needed to complete that research. However, the significance of the study focuses on different stages of leukemogenesis weighted equally. This paper provides insights to future researchers in choosing their research area related to RUNX1-RUNX1T1-induced AML.
Medicine,Engineering
What problem does this paper attempt to address?